418 related articles for article (PubMed ID: 11300867)
1. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
[TBL] [Abstract][Full Text] [Related]
2. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.
Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
4. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models.
Metzger TG; Paterlini MG; Portoghese PS; Ferguson DM
Neurochem Res; 1996 Nov; 21(11):1287-94. PubMed ID: 8947918
[TBL] [Abstract][Full Text] [Related]
5. The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.
Xu W; Chen C; Huang P; Li J; de Riel JK; Javitch JA; Liu-Chen LY
Biochemistry; 2000 Nov; 39(45):13904-15. PubMed ID: 11076532
[TBL] [Abstract][Full Text] [Related]
6. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
[TBL] [Abstract][Full Text] [Related]
7. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
8. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors.
Xu W; Li J; Chen C; Huang P; Weinstein H; Javitch JA; Shi L; de Riel JK; Liu-Chen LY
Biochemistry; 2001 Jul; 40(27):8018-29. PubMed ID: 11434771
[TBL] [Abstract][Full Text] [Related]
10. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes.
Portoghese PS
J Med Chem; 2001 Jul; 44(14):2259-69. PubMed ID: 11428919
[No Abstract] [Full Text] [Related]
11. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
[TBL] [Abstract][Full Text] [Related]
12. Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors.
Wang WW; Shahrestanifar M; Jin J; Howells RD
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12436-40. PubMed ID: 8618916
[TBL] [Abstract][Full Text] [Related]
13. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
14. 7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
Ohkawa S; DiGiacomo B; Larson DL; Takemori AE; Portoghese PS
J Med Chem; 1997 May; 40(11):1720-5. PubMed ID: 9171881
[TBL] [Abstract][Full Text] [Related]
15. Mercaptoacetate induces feeding through central opioid-mediated mechanisms in rats.
Stein JA; Znamensky V; Baumer F; Rossi GC; Pasternak GW; Bodnar RJ
Brain Res; 2000 May; 864(2):240-51. PubMed ID: 10802031
[TBL] [Abstract][Full Text] [Related]
16. Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: comparison with the distribution of mu, delta and kappa binding sites.
Gackenheimer SL; Suter TM; Pintar JE; Quimby SJ; Wheeler WJ; Mitch CH; Gehlert DR; Statnick MA
Neuropeptides; 2005 Dec; 39(6):559-67. PubMed ID: 16289278
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
Stevens WC; Jones RM; Subramanian G; Metzger TG; Ferguson DM; Portoghese PS
J Med Chem; 2000 Jul; 43(14):2759-69. PubMed ID: 10893314
[TBL] [Abstract][Full Text] [Related]
19. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
Fang X; Larson DL; Portoghese PS
J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669
[TBL] [Abstract][Full Text] [Related]
20. A chimeric analysis of the opioid receptor domains critical for the binding selectivity of mu opioid ligands.
Watson B; Meng F; Akil H
Neurobiol Dis; 1996 Feb; 3(1):87-96. PubMed ID: 9173916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
